Riesgo de las enfermedades tromboembólicas venosas de los fármacos oncológicos - page 15

Incidencia ETEA 1.4%

Metaanálisis Qi et al. Crit Rev Oncol Hematol. 2014

19 EC

9711 pacientes

Incidencia total ATE 1,5%

OR 2,26 IC95% 1,38-3,68; P=0,001

Evento más frecuente: isquemia cardíaca 67,4%

TKI con acción antiangiogénica

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,5,6,7,8,9,10,11,12,13,14 16,17,18,19,20,21,22,23